ANAVEX2-73 oral liquid for Rett Syndrome (EXCELLENCE Trial)

"ANAVEX2-73 is a medication that was first studied in 2019 by MAC Clinical Research. So far, 1 study has been completed with 2 more ongoing. The majority of these clinical trials are based in Vancouver, British Columbia."

"Research into ANAVEX2-73 oral liquid began in 2019 with a study sponsored by Anavex Germany GmbH. After the initial Phase 1 trial with a sample size of 450, the drug received approval for Phase 2 & 3 trials. Currently, there are 2 active trials being conducted in 5 countries and 32 cities."

"In total, 84 participants are required for this clinical trial. These individuals must meet the specified inclusion criteria. Patients can participate in this study from locations such as British Columbia Children's Hospital in Vancouver and Alberta Children's Hospital in Calgary."

"This particular study is for patients aged 5-17, but there are 382 trials for patients under 18 and 1023 trials for patients over 65."

"4 hospitals in Canada are recruiting patients for this trial, these include: British Columbia Children's Hospital in Vancouver, Alberta Children's Hospital in Calgary and Holland Bloorview Kids Hospital in Toronto. In addition, there are 4 other locations where recruitment is taking place."

"This trial, which was first posted on July 1, 2020, is actively recruiting patients, as indicated on clinicaltrials.gov. The most recent update was on September 4, 2022."

"This clinical trial is looking for 84 participants that currently suffer from Rett Syndrome. The age range for participants is 5-17. In addition to meeting these age requirements, it is also important that patients meet the following criteria: have a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening, have had a stable pharmacological treatment regimen for at least 4 weeks, not electively initiate new or modify ongoing interventions for the duration of the study, be at the post-regression stage, and be aged ≥ 5 years to 17 (inclusive)."